$44.4 M

CATB Mkt cap, 04-Dec-2018
Catabasis Pharmaceuticals Net income (Q2, 2018)-6.5 M
Catabasis Pharmaceuticals EBIT (Q2, 2018)-6.6 M
Catabasis Pharmaceuticals Cash, 30-Jun-201849.9 M

Catabasis Pharmaceuticals Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

500.0k

R&D expense

23.0m25.5m18.7m

General and administrative expense

8.6m10.1m8.9m

Operating expense total

31.7m35.6m27.6m

EBIT

(31.7m)(35.6m)(27.1m)

EBIT margin, %

(5419%)

Interest expense

978.0k837.0k462.0k

Net Income

(32.6m)(36.1m)(27.4m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

250.0k

R&D expense

6.4m6.8m5.9m5.4m4.5m4.8m5.2m4.2m

General and administrative expense

2.8m2.6m2.3m2.4m2.4m2.4m2.4m2.4m

Operating expense total

9.2m9.4m8.3m7.8m6.9m7.2m7.6m6.6m

EBIT

(9.2m)(9.4m)(8.3m)(7.8m)(6.9m)(7.0m)(7.6m)(6.6m)

EBIT margin, %

(2781%)

Interest expense

243.0k220.0k199.0k149.0k127.0k105.0k57.0k33.0k

Net Income

(9.4m)(9.4m)(8.4m)(7.9m)(7.0m)(7.0m)(7.7m)(6.5m)

Catabasis Pharmaceuticals Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

62.8m23.6m16.4m

Inventories

804.0k1.0m

Current Assets

63.6m39.5m17.5m

PP&E

504.0k568.0k321.0k

Total Assets

64.2m40.2m17.9m

Accounts Payable

1.3m1.4m773.0k

Current Liabilities

7.8m8.3m6.0m

Total Liabilities

11.1m6.1m

Additional Paid-in Capital

158.5m173.1m183.2m

Retained Earnings

(108.0m)(144.1m)(171.4m)

Total Equity

50.5m29.1m11.8m

Financial Leverage

1.3 x1.4 x1.5 x

Catabasis Pharmaceuticals Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(32.6m)(36.1m)(27.4m)

Depreciation and Amortization

202.0k395.0k304.0k

Inventories

(450.0k)(229.0k)

Accounts Payable

196.0k77.0k(632.0k)

Cash From Operating Activities

(29.8m)(32.9m)(26.8m)

Purchases of PP&E

(421.0k)(459.0k)(57.0k)

Cash From Investing Activities

(421.0k)(15.5m)14.9m

Cash From Financing Activities

78.3m9.2m4.7m

Interest Paid

684.0k582.0k327.0k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(9.4m)(18.9m)(27.3m)(7.9m)(14.8m)(21.9m)(7.7m)(14.1m)

Depreciation and Amortization

195.0k300.0k88.0k165.0k237.0k62.0k105.0k

Accounts Payable

2.5m1.8m1.6m210.0k178.0k(468.0k)650.0k(203.0k)342.0k(402.0k)

Cash From Operating Activities

(18.0m)(24.9m)(8.1m)(13.8m)(21.2m)(6.8m)(12.4m)

Purchases of PP&E

(388.0k)(436.0k)(9.0k)(39.0k)(57.0k)

Cash From Investing Activities

(19.0m)(21.3m)14.9m14.9m14.9m8.0k

Cash From Financing Activities

(1.6m)9.9m1.4m4.7m4.4m7.5m46.0m

Interest Paid

463.0k661.0k104.0k195.0k269.0k42.0k68.0k

Catabasis Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Catabasis Pharmaceuticals Employee Rating

5.01 votes
Culture & Values
5.0
Work/Life Balance
3.0
Senior Management
5.0
Salary & Benefits
5.0
Career Opportunities
5.0
Source